Zymeworks.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
Earlier this month
-
Zymeworks and Hoffmann-La Roche announced a collaboration agreement for the development of ZW209.Some support2 reports
-
Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Some support3 reports
-
Zymeworks management attended conferences in London and New York on October 15, 2026.Some support2 reports
One to three months ago
-
Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Some support4 reports1 development inside
-
Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Some support1 report
-
Stock trading activity for multiple companies, including Ultragenyx, Casey’s General Stores, Plains All American Pipeline, Weyerhaeuser, Zymeworks, and Ciena, was reported on the Nasdaq exchange on September 3, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Zymeworks was listed on the electronic stock exchange, with data aggregated by MarketBeat.Some support2 reports
-
Both Zymeworks and Panbela Therapeutics are small-cap biopharma companies.Some support1 report
-
CTIM-76 targets different indications than ZW191.Some support1 report
-
Both Zymeworks and Petros Pharmaceuticals are small-cap medical companies in the biotech sector focusing on men's health therapeutics in the US.Some support1 report
-
The FDA cleared the IND application for ZW251, a product of Zymeworks.Some support4 reports1 development inside
-
Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.Some support1 report
-
Zymeworks announced a decision from Vancouver.Some support4 reports
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Zymeworks shares underperformed the S&P 500 on August 8, 2025.Some support1 report
-
Zymeworks management participated in investor conferences held in Boston on August 19, 2025.Some support2 reports
-
Benzinga provided stock analysis on Zymeworks on September 3, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Zymeworks
Events traced to Zymeworks, step by step, newest firstAround Zymeworks this week
News at the entities that move Zymeworks most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Zymeworks
-
Hoffmann-La Roche StructuralOmar Khwaja, a Fellow of the Royal College of Physicians, leads clinical research at Cancer Research UK.Moves Zymeworks
-
Nasdaq StructuralWindward Bio successfully listed on the Nasdaq exchange and is a portfolio company of Qiming Venture Partners.Moves Zymeworks
-
Jefferies Financial Group Mentioned togetherAlabama retirement systems lowered their position while Amundi increased its stake and Jefferies issued a hold rating.Moves Zymeworks
-
Ireland StructuralWRc facilitated negotiations for a pay deal in Ireland in September 2026.Moves Zymeworks
-
Truist Financial Mentioned togetherSylvamo received rating updates from Bank of America, Truist Financial, and RBC on July 19, reiterating neutral ratings and lowering price targets.Moves Zymeworks
Connections
The 22 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jazz Pharmaceuticals Structural
A and B maintain a strategic partnership where B commercializes its assets using A's global reach, with financial milestones tied to A's regulatory successes.
-
Johnson & Johnson Structural
Johnson & Johnson utilizes Zymeworks' proprietary technology platform for the development and production of clinical-stage antibodies.
-
Paul Moore Structural
Paul Moore holds the formal position of Chief Scientific Officer at Zymeworks.
-
FDA Structural
FDA formally regulates Zymeworks, granting product approvals and clearing necessary applications.
-
Hoffmann-La Roche Structural
Roche and Zymeworks have a collaboration agreement where Roche funds and develops ZW209.
-
Nasdaq Structural
Zymeworks is a company publicly listed and trades on the Nasdaq stock exchange.
-
OMERS Transactional
OMERS subscribed to a non-recourse note related to Zymeworks.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group issued a buy rating on Zymeworks.
Show all 22 connections
-
Mylan Operational
The evidence suggests a functional partnership where Zymeworks leverages market access provided by the entity currently operating under the Viatris umbrella, which is the operational successor to Mylan.
-
Ireland Structural
Zymeworks leverages Ireland's fiscal environment by utilizing its tax attributes.
-
New York Shared context
Zymeworks management is observed attending conferences in New York.
-
Chicago Shared context
Zymeworks participates in scientific meetings held in Chicago.
-
New York Shared context
Zymeworks conducts business activities, including investor conferences and operations, within the geographic area of New York.
-
Citigroup Mentioned together
Citigroup provided a market outperform rating on Zymeworks.
-
Boston Shared context
Zymeworks holds investor meetings and participates in conferences within the city of Boston.
-
European Society for Medical Oncology Mentioned together
Zymeworks presented clinical data at the European Society for Medical Oncology Congress.
-
Truist Financial Mentioned together
Truist Financial raised its price target on Zymeworks, signaling market confidence in the company.
-
MarketBeat Mentioned together
MarketBeat aggregates data on Zymeworks as part of its function as a financial news hub.
-
Vancouver Shared context
Zymeworks is headquartered and conducts its operations within Vancouver, British Columbia.
-
London Shared context
Zymeworks management is observed participating in conferences held in London.
-
company Shared context
Zymeworks is described as a company that manages licensed healthcare assets and develops biotherapeutics.
-
Jason McCarthy Mentioned together
No relationship between Zymeworks and Jason McCarthy was observed in the provided evidence.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
2 eventsAugust 2026
1 eventShow 2 earlier months
July 2026
2 eventsJune 2026
10 events- Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.
- Both Zymeworks and Petros Pharmaceuticals are small-cap medical companies in the biotech sector focusing on men's health therapeutics in the US.
- The FDA cleared the IND application for ZW251, a product of Zymeworks.
- Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.
- Zymeworks announced a decision from Vancouver.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Zymeworks shares underperformed the S&P 500 on August 8, 2025.
- Zymeworks management participated in investor conferences held in Boston on August 19, 2025.
- Benzinga provided stock analysis on Zymeworks on September 3, 2025.